News stories about BioDelivery Sciences International (NASDAQ:BDSI) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 46.7289104199374 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research analysts have recently issued reports on the company. HC Wainwright assumed coverage on BioDelivery Sciences International in a research report on Sunday, September 10th. They set a “buy” rating and a $5.00 price objective for the company. Cantor Fitzgerald set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Finally, Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $4.29.

BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.10 during trading hours on Wednesday, reaching $2.85. The company’s stock had a trading volume of 1,039,800 shares, compared to its average volume of 834,600. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a one year low of $1.55 and a one year high of $3.60. The stock has a market capitalization of $153.68, a price-to-earnings ratio of 31.67 and a beta of 0.74.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. During the same period in the previous year, the company earned ($0.30) earnings per share. The company’s revenue for the quarter was up 215.1% compared to the same quarter last year. research analysts predict that BioDelivery Sciences International will post 0.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with's FREE daily email newsletter.